QRG Capital Management Inc. Decreases Holdings in GSK plc (NYSE:GSK)

QRG Capital Management Inc. trimmed its position in shares of GSK plc (NYSE:GSK - Free Report) by 16.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 157,296 shares of the pharmaceutical company's stock after selling 31,812 shares during the period. QRG Capital Management Inc.'s holdings in GSK were worth $5,320,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in GSK. Allspring Global Investments Holdings LLC grew its holdings in GSK by 40.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 11,764 shares of the pharmaceutical company's stock valued at $481,000 after purchasing an additional 3,405 shares during the last quarter. Pinnacle Associates Ltd. grew its stake in GSK by 6.2% in the 3rd quarter. Pinnacle Associates Ltd. now owns 32,921 shares of the pharmaceutical company's stock worth $1,346,000 after acquiring an additional 1,912 shares in the last quarter. JFS Wealth Advisors LLC grew its stake in GSK by 1,429.4% in the 3rd quarter. JFS Wealth Advisors LLC now owns 29,426 shares of the pharmaceutical company's stock worth $1,203,000 after acquiring an additional 27,502 shares in the last quarter. US Bancorp DE grew its stake in GSK by 12.2% in the 3rd quarter. US Bancorp DE now owns 236,770 shares of the pharmaceutical company's stock worth $9,679,000 after acquiring an additional 25,781 shares in the last quarter. Finally, Lincluden Management Ltd. grew its stake in GSK by 1.3% in the 3rd quarter. Lincluden Management Ltd. now owns 66,001 shares of the pharmaceutical company's stock worth $2,698,000 after acquiring an additional 833 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors.

GSK Stock Up 1.0 %

Shares of NYSE GSK traded up $0.38 during midday trading on Monday, reaching $37.97. 3,978,664 shares of the company's stock traded hands, compared to its average volume of 4,929,240. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The stock's 50 day simple moving average is $35.07 and its 200-day simple moving average is $37.20. GSK plc has a one year low of $31.72 and a one year high of $45.92. The company has a market cap of $78.70 billion, a price-to-earnings ratio of 23.88, a P/E/G ratio of 1.12 and a beta of 0.64.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. On average, analysts predict that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a dividend of $0.3932 per share. This is a boost from GSK's previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a yield of 4.14%. GSK's dividend payout ratio is presently 98.74%.

Wall Street Analyst Weigh In

A number of brokerages have commented on GSK. Jefferies Financial Group downgraded shares of GSK from a "buy" rating to a "hold" rating and dropped their target price for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 7th. Morgan Stanley began coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. Seven research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.